Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Intellia Therapeutics Inc (NASDAQ: NTLA) was $12.78 for the day, down -10.25% from the previous closing price of $14.24. In other words, the price has decreased by -$10.25 from its previous closing price. On the day, 7.32 million shares were traded. NTLA stock price reached its highest trading level at $14.32 during the session, while it also had its lowest trading level at $12.48.
Ratios:
Our analysis of NTLA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.10.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 01 ’25 when Clark Eliana sold 1,022 shares for $9.82 per share. The transaction valued at 10,036 led to the insider holds 95,369 shares of the business.
Dube Michael P sold 2,503 shares of NTLA for $24,905 on Jul 02 ’25. The VP, Chief Accounting Officer now owns 57,137 shares after completing the transaction at $9.95 per share. On Jun 30 ’25, another insider, GOODMAN JESSE, who serves as the Director of the company, sold 1,547 shares for $9.56 each. As a result, the insider received 14,789 and left with 25,906 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1323790720 and an Enterprise Value of 939301760. For the stock, the TTM Price-to-Sale (P/S) ratio is 29.05 while its Price-to-Book (P/B) ratio in mrq is 1.70. Its current Enterprise Value per Revenue stands at 20.613 whereas that against EBITDA is -1.77.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.35, which has changed by -0.51773584 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $27.42, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is 30.99%, while the 200-Day Moving Average is calculated to be 13.12%.
Shares Statistics:
NTLA traded an average of 4.71M shares per day over the past three months and 4672330 shares per day over the past ten days. A total of 103.54M shares are outstanding, with a floating share count of 97.42M. Insiders hold about 5.95% of the company’s shares, while institutions hold 92.18% stake in the company. Shares short for NTLA as of 1751241600 were 30130358 with a Short Ratio of 6.40, compared to 1748563200 on 31557488. Therefore, it implies a Short% of Shares Outstanding of 30130358 and a Short% of Float of 33.110002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
